Cholesterol absorption inhibition and bile acid binding in the intestine (None)

Cholesterol absorption inhibition coupled with bile acid binding in the intestine represents an important therapeutic strategy targeting hypercholesterolemia. The small intestine absorbs dietary and biliary-derived cholesterol primarily through the action of the Niemann-Pick C1-Like 1 protein (NPC1L1), which facilitates endocytosis of micellarized free cholesterol into enterocytes. Drugs such as ezetimibe selectively inhibit this transporter’s function, reducing incorporation into chylomicrons that deliver absorbed sterols back to the liver. This decreases plasma low-density lipoprotein (LDL) concentrations by limiting exogenous sources. Separately but complementarily, certain agents known as bile acid sequestrants bind negatively charged bile salts within the gut lumen preventing their reabsorption. Since these molecules are normally recycled via enterohepatic circulation after being synthesized from hepatic free cholesterol, their loss forces increased conversion from circulating LDL-derived pools. Together these mechanisms reduce systemic exposure to proatherogenic lipoproteins thereby lowering cardiovascular risk. Combination therapy with statins—which block endogenous synthesis—can synergistically optimize lipid profiles. Natural compounds like phytosterols also contribute similarly by competing at sites critical for micelle formation or transport. This approach addresses both major sources contributing to plasma LDL—intestinal uptake and hepatic synthesis—and has become integral for managing dyslipidemias resistant or insufficiently responsive to monotherapy[2][3][4][1].

Other names

Cholesterol absorption inhibitorsIntestinal cholesterol uptake inhibitionBile acid sequestration in intestineNPC1L1 inhibition (specific molecular target for cholesterol absorption inhibitors like ezetimibe)

Inhibition of NPC1L1 transporter-mediated endocytosis of micellar cholesterol into enterocytes by drugs like ezetimibe, reducing chylomicron formation and hepatic delivery of absorbed cholesterol. Binding and sequestration of bile acids in the intestine by resins/fibers prevents their reabsorption, increasing fecal excretion. This reduces enterohepatic recycling leading to increased hepatic conversion of cholesterol into new bile acids. Overall effect leads to decreased plasma LDL-cholesterol due to reduced intestinal input plus compensatory upregulation of hepatic LDL receptors enhancing clearance.